A BS TRACT: Background: Elevated uptake of the [ 18 F]AV-1451 tau-PET ligand has been observed crosssectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [ 18 F]AV-1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy. Methods: Sixteen subjects with PSP underwent 2 serial [ AV-1451 uptake was calculated for each scan for regions of interest across the brain and divided by uptake in cerebellar crus to create standard uptake value ratios. Midbrain volume on MRI was also calculated for each scan. Sample sizes required to power placebo-controlled treatment trials were calculated.
Results: Rate of midbrain atrophy was significantly increased in PSP compared with controls. [ 18 F]AV-1451 regional change measures were significantly increased in PSP compared with controls in the pallidum, precentral cortex, dentate nucleus of the cerebellum, and midbrain. Change over time in the PSP Rating Scale correlated with change in midbrain volume but did not correlate with change in the [ 18 F]AV-1451 measures. Smallest samplesize estimates were obtained with rate of midbrain atrophy, followed by the PSP Rating Scale, with both outperforming [ 18 F]AV-1451 measures.
Conclusions: [
Progressive supranuclear palsy (PSP) is a devastating neurodegenerative disease. Patients with PSP typically have difficulty with gait and posture, frequently fall, and have vertical supranuclear gaze palsy on neurological examination. 1, 2 At autopsy, the vast majority of patients clinically diagnosed with PSP have deposition of 4-repeat tau [3] [4] [5] ; hence, tau is a major target for future treatments of PSP, and PSP subjects are being targeted for clinical treatment trials for tau-based therapies. Hence, biomarkers that track disease progression in PSP are extremely valuable. At present, the most studied and validated biomarkers come from MRI, 6 with rate of midbrain atrophy confirmed as a reliable biomarker in PSP, which allows small samplesize estimates for clinical treatment trials. [7] [8] [9] However, MRI only provides a surrogate biomarker of underlying pathology. No disease-specific biomarker currently exists that can track progression of tau pathology during life that could be used as an outcome measure in treatment trials. 
Methods

Subjects
Sixteen subjects that fulfilled clinical criteria for probable PSP 2 underwent 2 serial [
18 F]AV-1451 PET scans and accompanying 3 T MRI with follow-up intervals of approximately 12 months. All subjects had been identified from the Department of Neurology, Mayo Clinic, and consecutively recruited into an National Institutes of Health-funded prospective longitudinal PSP study by a neurodegenerative specialist and PSP expert (K.A.J.). All baseline evaluations occurred between February 18, 2015, and December 6, 2016, and follow-ups were completed between March 1, 2016, and December 5, 2017. Subjects were included in the study if they met criteria for probable PSP, had symptoms for ≤5 years, and were able to ambulate at least short distances independently. Of the 16 subjects, 14 fulfilled clinical criteria for PSP-Richardson's syndrome, 1 met criteria for PSPparkinsonism, and 1 met criteria for PSP-progressive gait freezing. 2 Two subjects with PSP-Richardson's syndrome also met criteria for PSP-speech/language. 2 One subject has died and had pathologically confirmed PSP.
All subjects underwent clinical and neurological examinations and completed standardized and validated testing, including the PSP Rating Scale (PSPRS) 22 as a measure of clinical disease severity, the PSP Saccadic Impairment Scale 23 26 The study was approved by the Mayo institutional review board. All subjects consented to the research.
Neuroimaging Analyses
Tau-PET imaging was performed using the [ F]AV-1451 was administered, followed by a 20-minute PET acquisition performed 80 minutes after injection. Partial volume correction (PVC) of PET data was performed using a 2-compartment model. 27 All subjects had a 3 T MPRAGE sequence performed at the time of the tau-PET (TR/TE/T1, 2300/3/900 milliseconds; flip angle, 8 ; 26-cm field of view; 256 × 256 in-plane matrix with a phase FOV of 0.94; slice thickness of 1.2 mm; in-plane resolution of 1 mm). MPRAGE images were each segmented and corrected for intensity inhomogeneity using SPM12 Unified Segmentation 28 with modifications and tissue priors from the Mayo Clinic Adult Lifespan Template (MCALT; https://www.nitrc.org/projects/mcalt/). 29 Midbrain volume was measured for each scan by propagating a template-drawn midbrain volume mask into the native space of each patients scan and summing segmented pervoxel gray-and white-matter probabilities. 30 The template-drawn midbrain volume mask was traced using Analyze software (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN) according to previously published guidelines. 31 [ 18 F]AV-1451 images were each coregistered and resampled to the corresponding MPRAGE of the subjects using SPM12 6-degree-of-freedom rigid body registration and B-spline interpolation. All regions of interest were defined in MCALT space. The dentate nucleus of the cerebellum was defined as previously described 20 on MCALT, and voxels containing the dentate nucleus of the cerebellum were removed from all other cerebellar regions of interest. The midbrain volume mask described above 31 was transformed to MCALT. The Deep Brain Stimulation Intrinsic Template Atlas 32 was transformed into MCALT space and used to define regions for the subthalamic nucleus, red nucleus, and substantia nigra. All other regions of interest were defined using the MCALT atlas. For each subject MPRAGE, a nonlinear mapping to MCALT was created using Advanced Normaliation Tools, 33 and this mapping was used to automatically localize all regions on the native MPRAGE image using GenericLabel interpolation. Each region was then masked to include only gray-or white-matter-segmented voxels, and PET regional values were measured as the median image intensity across these voxels. Regional median values were divided by the median uptake in cerebellar crus gray matter to create standard uptake ratios (SUVRs). The crus region was selected to provide cerebellar gray matter in relative isolation from CSF spaces and to avoid being adjacent to parahippocampal, fusiform, and lingual gyri to avoid bleed-in signal from tau pathology. 34 Left and right hemisphere structures were combined for each region of interest. Manual quality control checks were performed on the [
18 F]AV-1451 and MPRAGE scans, as well as on the segmentations and registrations of the atlas regions of interest onto the [ 18 F]AV-1451 scans. Two subjects were excluded from the MRI analysis because of motion artifacts on one of their MRI scans. However, all 16 subjects were included in the tau-PET analysis because the atlas-to-[
18 F]AV-1451 registrations were acceptable.
An initial assessment of the longitudinal data was performed using 52 regions of interest across all cortical and subcortical structures. This allowed us to investigate general patterns in the data in an unbiased manner. A smaller, more specific set of regions was then used to assess rates of change in [ 18 F]AV-1451 uptake over time. The smaller set of 15 regions included 9 subcortical and brain stem regions that have been shown to have tau uptake in cross-sectional studies (midbrain, thalamus, dentate nucleus of the cerebellum, globus pallidus, caudate, putamen, subthalamic nucleus, substantia nigra, red nucleus) and 4 cortical regions that show high tau deposition at autopsy 35, 36 (superior frontal, precentral, postcentral, supplementary motor area), as well as 2 cortical regions that are typically relatively unaffected pathologically in PSP (entorhinal cortex and occipital lobe).
Statistical Analysis
For each subject, we calculated the annualized change of tau-PET, defined as follow-up SUVR minus baseline SUVR divided by time in years. We summarized the annual change measures by reporting the mean and 95% CI. To investigate the differences in annualized change between PSP and control subjects across the 15 regions of interest, we calculated the area under the receiver operating characteristic curve (AUROC), a nonparametric effect-size measure that is independent of the underlying scales of the data. 37 In general, the higher the AUROC estimates, the better is the discrimination between groups. To correct for age, for each ROI, we fitted a linear regression between tau SUVR and age. The residual values from the regression were used for the AUROC analysis. P values and 95% confidence intervals for the regions of interest were based on the link between AUROC and the Mann-Whitney U statistic. 38 The P values were also adjusted for multiple comparisons using false discovery rate correction. A nonparametric analysis approach was appropriate for our data because the [ 18 F]AV-1451 estimates were not normally distributed. However, for comparison purposes, we also provide the parametric Cohen's D effect-size metric. The Cohen's d estimate was the difference in means scaled by the residual standard deviation from an ageadjusted linear regression model. We investigated differences in annualized midbrain volume change between PSP and controls using this same analytical approach. Spearman's correlations were calculated between annualized change in the PSPRS and annualized change in imaging metrics, and between baseline and annualized change measures for [
18 F]AV-1451. Sample-size requirements per treatment arm for a placebo-controlled treatment trial were estimated for rates of midbrain atrophy, change in PSPRS over time, and change in the top [
18 F]AV-1451 measures. Estimated sample sizes needed for PSP subjects to detect a 20% reduction in the rate of change based on 80% and 90% power, 2-sided, 2-sample t test, with an α of 0.05 were calculated. Statistical analyses were performed using PET scans that had undergone PVC, and also repeated using PET scans without PVC. The statistical analyses were performed using R version 3.4.1.
Results
Evaluation of Subject-Level [ 18 
F]AV-1451 Change
Tau-PET SUVRs across all regions are shown for each scan within each subject in Figure 1 . The SUVR profile across regions remains relatively consistent over time in all subjects. However, the regional patterns of change over time varied across subjects. Subject 13 (Supplemental Fig. 1 ) showed increases in uptake over time across nearly all cortical and subcortical regions. Patterns of increased uptake predominantly in the dentate nucleus of the cerebellum and brain stem regions were observed in subjects 1, 2, 4, 8, and 15, with increases observed in frontal regions in subjects 3, 10, 11, and 12. Subjects 6 and 16 (Supplemental Fig. 1 ) showed subtle decreases in uptake in the midbrain, dentate nucleus of the cerebellum, and putamen, with subject 6 also showing decreases in frontotemporal regions, similar to subject 7. Regional profiles were very similar when using PET scans without PVC.
Regional Comparisons of PSP Patients and Controls
Rate of midbrain atrophy on 3 T MR imaging was significantly increased in the PSP subjects compared with controls, with an AUROC estimate of 0.93 to differentiate the 2 groups (Table 2 ). In the [ 18 F]AV-1451 analysis, the midbrain, pallidum, and precentral cortex showed significantly increased rates of uptake in PSP compared with controls, with AUROCs ranging from 0.75 to 0.79 ( Table 2 ). The dentate nucleus of the cerebellum and subthalamic nucleus also showed trends for increased rates of uptake in PSP compared with controls (AUROCs, 0.71 and 0.70), but these results did not survive correction for multiple comparisons. AUROC estimates were very similar when age effects were removed. In the analysis without PVC, the pallidum, precentral cortex, dentate nucleus of the cerebellum, and midbrain showed significantly increased rates of [ 18 F]AV-1451 uptake in PSP compared with controls, with AUROCs ranging from 0.71 to 0.76, with trends for increased rates of uptake in the subthalamic nucleus and substantia nigra (AUROCs, 0.69 and 0.68); see Supplemental Table 1 .
Correlations With Baseline Uptake and Disease Severity in PSP
Change in midbrain volume showed a reasonably strong correlation with change in PSPRS over the 12-month interval (r = -0.48, P = 0.09). However, we did not observe any significant correlations between change in [ 18 F]AV-1451 uptake over time for the midbrain, precentral cortex, dentate nucleus of the cerebellum, or pallidum and change in the PSPRS (Fig. 2) . We also did not see any significant associations between baseline [ (Fig. 2) . These 
Sample-Size Estimates
The smallest sample-size estimates were achieved with rate of midbrain volume followed by rate of change in the PSPRS (Table 3 ). Both these metrics provided smaller sample-size estimates than the [ [39] [40] [41] The pallidum, midbrain, and dentate nucleus of the cerebellum have also consistently shown elevated [ 18 F]AV-1451 in PSP compared with controls in cross-sectional studies. [16] [17] [18] 20, 21 Elevated uptake in cortical regions including the precentral cortex has been observed in some cross-sectional studies, 20, 21 although not all, 17, 18 and uptake was typically not as striking as that observed in the subcortical structures. 20, 21 Our findings suggest that the precentral cortex may be actively accumulating tau at this point in the disease, perhaps reflecting disease spread from subcortical structures to the cortex. However, the amount a subject changes over time in these regions is not related to the amount of uptake at baseline, perhaps telling us something biological about disease spread or reflecting noise in the measurements. The regions of interest placed on the subthalamic nucleus and substantia nigra also performed reasonably well in our longitudinal analysis, likely reflecting that they are both capturing the elevated signal observed in the midbrain in PSP subjects. However, neither performed as well as the midbrain region of,interest, which is larger and subsumes both these brain stem nuclei.
Individual patterns of change in uptake did show variability, however, with some subjects showing evidence for increased [ 18 F]AV-1451 uptake, but others showing decreased uptake over time. We also had a subject who stood out because increased uptake was observed across all regions of the brain. This variability likely reduced power in the group-level results. Of course, the difficulty in interpreting these longitudinal tau-PET results is that we have no biologic marker documenting how tau burden changes over the course of this disease. Pathological studies can only sample 1 time at the end of the disease. Although one might assume that tau pathology gradually accumulates over the course of the disease, it has been found that some oligodendroglial tau pathology actually decreases with disease duration in PSP. 42 In addition, the accumulated tau burden at any point may be partially offset by physiological degradation of tau aggregates. 43 The variability we observed across subjects could reflect this biological heterogeneity. Furthermore, we have no current assurances that [
18 F]AV-1451 tau-PET is providing an accurate measure of the burden of underlying 4R tau in PSP. Instead, it may reflect off-target binding to something other than 4R tau. If this is the case, then our data suggest that whatever the off-target binding site is, it does increase over time in PSP.
Despite observing regions with increasing [ did not perform as well as midbrain volume as a disease biomarker in PSP. An important aspect of a disease biomarker is that it should relate to progression of the disease. This is the case for rate of midbrain atrophy, which we found to correlate to change over time on the PSPRS in our cohort. Others have similarly observed good correlations between midbrain measures and disease severity in PSP.
9,44-46 However, we did not observe any correlation between decline in disease severity and longitudinal measures of [
18 F]AV-1451. Furthermore, sample-size estimates for clinical trials were much smaller for rate of midbrain volume compared with the [
18 F]AV-1451 measures, with only 94 subjects required per treatment arm with rate of midbrain volume loss for a trial with 80% power to detect a 20% treatment effect. These estimates are roughly in line with those obtained in previous studies for rate of midbrain volume change. [7] [8] [9] In comparison, 521 subjects per treatment arm would be required when using the pallidum, which was the best of the [ 18 F]AV-1451 measures. Of note, we found that the sample-size estimates were the smallest and the effect sizes of the difference between PSP and controls were the largest, when using PVC data compared with estimates without PVC. There is a current lack of consensus in the field concerning the value of PVC in [ 18 F]AV-1451 analysis, but in this situation it does increase power slightly. Sample-size estimates from the PSPRS were also smaller than those from the [
18 F]AV-1451 measures, although it did not perform as well as rate of midbrain volume, consistent with previous findings. Still statistically significant (adjusted P or q < 0.05) after controlling for false discovery rate.
Strengths of our study include that our cohort consisted of 3 clinical variants of PSP, which may increase generalizability to other PSP cohorts, and our findings were very similar in the analysis with and without PVC, with the same top set of regions identified in both analyses. However, our findings may not generalize to other variant syndromes of PSP that we did not include, and the number of subjects was too small to allow us to perform analyses across the different clinical variants. Future studies with larger numbers of subjects will need to determine whether patterns of change in [ It is important to also acknowledge that our results may not generalize to patients earlier in the disease course. The longitudinal trajectory of [
18 F]AV-1451 changes has not yet been established in PSP, and it is quite possible that rates of change may be greatest in earlier disease stages and could perform better than MRI measures in this phase of the disease. In addition, a limitation of the study is our necessary use of lateuptake SUVR images. SUVR images are less reliable than PET quantification methods using full-dynamic acquisitions, and longitudinal studies using SUVR can be confounded by differences in brain perfusion. 47 However, late-uptake scans with SUVR remain the most common method for PSP studies because of the large increase in cost, patient burden, and scanner access required for full-dynamic acquisitions. Performing full-dynamic scans for AV-1451 would require more than 100 minutes of scan time, rather than 20 minutes, and this was not feasible for our study.
Our study provides some evidence that [ 
